Search Bar & Filters
Found 448 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the use of 3D ultrasound imaging to guide standard care procedures such as ablation or biopsies of liver or kidney tumours. This observational study compares 3D ultrasound with conventional 2D ultrasound and checks the imaging results against pre- and post-procedure CT scans to assess how well tumours are removed or targeted during biopsies. The 3D ultrasound method uses a special assembly to move the ultrasound transducer in precise steps, creating detailed 3-dimensional images from multiple 2D images. During the study, patients undergoing liver or kidney tumour ablation or biopsy will be imaged using both standard care and 3D ultrasound devices. These devices record image data passively while the medical procedures are performed. The 3D ultrasound images are processed with specialized software to create volumes that allow viewing the area of interest from different angles. This imaging will be compared with CT images to verify the accuracy of tumour removal or biopsy targeting. Participants will be imaged by physicians during their scheduled ablation or biopsy procedures. The study involves collecting ultrasound image data during the treatment and analyzing these images afterward. Researchers will review the guidance and targeting accuracy of the needles used during these procedures as the primary outcome. The study is conducted by Western University, Canada, and patients who are well enough to consent and undergoing these standard care procedures are eligible to participate.
Actively Recruiting
Researchers are evaluating how a 12-week daily inhaler therapy combining fluticasone furoate, umeclidinium, and vilanterol affects adults aged 50 to 85 with moderate to severe COPD. The study includes equal numbers of males and females with persistent symptoms and compares those at low and high risk of COPD flare-ups. It aims to understand if this triple therapy improves lung ventilation as measured by 129-Xenon MRI and how this relates to lung function tests. Participants will use a single Ellipta inhaler containing the three medications once daily for 12 weeks, with an optional additional 48 weeks of treatment. They will attend two main visits at baseline and after 12 weeks, with an optional third visit at 48 weeks to assess longer-term effects. The study observes participants responses during and after therapy. During visits, participants undergo various lung function tests including spirometry, plethysmography, oscillometry, and exhaled nitric oxide measurement. They will have 129-Xe MRI scans and chest CT scans before and after bronchodilator use. Questionnaires assessing respiratory symptoms, health status, and exertion are completed, along with a blood draw for inflammatory markers. Researchers measure ventilation defect percentage and lung function changes to evaluate therapy effects over time.
Actively Recruiting
Researchers are investigating the use of 3D ultrasound imaging during brachytherapy treatment for gynecological cancers, including primary or recurrent vaginal, endometrial, and cervical cancers. This study aims to improve needle placement accuracy in interstitial or intra-cavitary brachytherapy, which is important for delivering adequate radiation doses to tumors while protecting healthy pelvic organs. Currently, there is no standard real-time image guidance for needle insertion in these procedures, which this research seeks to address. The study involves patients receiving gynecological brachytherapy using a device-based approach, where needles and applicators are inserted under general anesthesia with guidance from clinical exams and pre-procedure MRI. An investigational 3D ultrasound device will be used during the procedure to provide real-time volumetric imaging of needle pathways, improving upon the limitations of standard 2D ultrasound. After the procedure, CT scans are performed for radiation planning. Participants will undergo imaging assessments including MRI before treatment and CT after treatment, with the main focus on measuring the accuracy of needle placement over a 16-month period. The study team will evaluate how effectively the 3D ultrasound helps avoid needle insertion into pelvic organs and optimizes tumor dose coverage. Patient safety and treatment monitoring will be conducted alongside these measurements within the study timeline.
Actively Recruiting
Researchers are investigating new treatment options for people with locally advanced or metastatic colorectal cancer mCRC that cannot be removed by surgery and has a specific gene mutation called KRAS G12C. The study aims to evaluate the safety and tolerance of combining calderasib, cetuximab, and mFOLFOX6 chemotherapy compared to the standard treatment of mFOLFOX6 with or without bevacizumab. This research is a phase 3 clinical trial focused on improving outcomes for this specific patient group. Participants will be assigned to one of two groups. One group receives calderasib tablets orally, cetuximab every two weeks, and mFOLFOX6 chemotherapy including oxaliplatin, leucovorin or levofolinate calcium, and 5-fluorouracil every two weeks. The other group receives mFOLFOX6 chemotherapy with or without bevacizumab or a bevacizumab biosimilar, also administered every two weeks. Treatment continues until doctors decide to stop based on specific criteria. During the study, participants will be closely monitored for side effects and treatment tolerability, with evaluations lasting up to about 44 months in the first part and up to 5 years in the second part. Researchers will collect data on progression-free survival, response rates, overall survival, and quality of life using various questionnaires. Safety assessments and tracking of any adverse events will be conducted regularly throughout the study.
Actively Recruiting
Researchers are evaluating new treatment options for metastatic cervical cancer, a condition where cancer has spread from the cervix to other parts of the body. This study focuses on the safety and effectiveness of combining sacituzumab tirumotecan sac-TMT, pembrolizumab, and bevacizumab, compared to standard treatments. The research aims to understand how well these medicines work together and whether they help people live longer or delay cancer progression. The study has two parts. In Part 1, eligible participants receive sac-TMT with pembrolizumab and bevacizumab to assess safety. In Part 2, all participants first undergo standard induction treatment with pembrolizumab, paclitaxel, and cisplatin or carboplatin, with optional bevacizumab. Those whose cancer does not worsen are randomized to receive either pembrolizumab alone or sac-TMT plus pembrolizumab, with optional bevacizumab for maintenance treatment. Treatments are given by intravenous infusion at specified doses and schedules over several months. Participants will be closely monitored throughout the study with regular visits to assess safety, cancer progression, and quality of life. Researchers will track adverse events, treatment tolerability, progression-free survival, and overall survival. Quality of life questionnaires and physical functioning assessments are included to understand the impact of treatment. The study duration may extend up to approximately 69 months for safety follow-up, with various outcome measures evaluated at set intervals.
Actively Recruiting
Researchers are evaluating the safety, effectiveness, and how the body processes a medication called NXT007 compared with another treatment called emicizumab for people aged 12 years and older who have severe or moderate congenital hemophilia A without inhibitors or any severity of hemophilia A with inhibitors. The study is a Phase III clinical trial focused on treatment to understand these two prophylaxis options better. Participants are randomly assigned to receive either NXT007 or emicizumab prophylaxis during the main treatment period. Emicizumab is given with a loading dose of 3 mgkg weekly for 4 weeks, followed by maintenance doses at different intervals, while NXT007 is administered subcutaneously as an integrated drug-device product. After the main treatment period, participants on NXT007 can continue this treatment, and those on emicizumab can switch to NXT007 during an open-label extension phase. During the study, participants will be monitored for bleeding rates, treatment burden, and safety through various assessments including questionnaires and blood tests. Researchers will track adverse events, immune responses to NXT007, and drug levels over approximately 3.5 years. The primary measure is the annualized rate of treated bleeds from month 2 onward, with study completion expected in 2032.
Actively Recruiting
Researchers are evaluating the safety, optimal dose, and effectiveness of a combination treatment involving BNT323 trastuzumab pamirtecan and BNT327 pumitamig in people with advanced breast cancer. This includes patients with hormone receptor-positive or negative, HER2-positive, HER2-low, HER2-ultralow, HER2-null breast cancer, or triple-negative breast cancer. The study is a Phase III, multi-site, open-label trial designed to find the best dose and assess the treatments effects in these groups. The study has two parts. Part 1 involves dose escalation where participants with chemotherapy-pretreated advanced breast cancer receive various dose levels of BNT323 plus BNT327 to determine the recommended Phase 2 dose. Part 2 includes dose optimization and exploratory groups, beginning after Part 1s completion. In Part 2 Cohort 1, participants are randomized into four arms to receive either the combination at the recommended dose, the combination at another dose, BNT323 alone, or BNT327 alone. Other cohorts receive the recommended dose without randomization. Participants will undergo treatment cycles with intravenous infusions of the study drugs and be monitored for safety, side effects, and tumor response for up to 36 months. Assessments include tracking dose-limiting toxicities, adverse events, tumor scans, and response rates. Safety monitoring continues up to 90 days after the last dose. The study aims to provide detailed information on the best dose, safety, and potential benefits of these treatments for advanced breast cancer.
Actively Recruiting
Testicular cancer is a rare adult cancer but the most common solid tumor in young men, with about 90% being germ cell tumors classified as seminoma or non-seminoma. Around 20% of seminoma patients have clinical stage II disease with limited retroperitoneal lymph node metastases. This trial explores an alternative to standard radiotherapy or chemotherapy treatments, which carry risks of serious short- and long-term side effects, by evaluating the role of surgery called Primary Retroperitoneal Lymph Node Dissection RPLND.
Actively Recruiting
Healthy Volunteer
Researchers are investigating the effects of Lysoveta, a hydrolyzed krill oil supplement rich in omega-3 fatty acids, on cognitive function in healthy adults aged 50 to 75 who experience self-perceived memory problems. This randomized, placebo-controlled, triple-blind trial aims to compare the impact of Lysoveta versus a placebo on episodic, working, and spatial memory using the Computerized Mental Performance Assessment System COMPASS. Participants are randomly assigned to one of two groups one group receives three capsules daily containing 500 mg each of Lysoveta, while the other group takes placebo capsules containing a mix of medium-chain triglyceride, maize, olive, and palm kernel oils. The study lasts for 112 days, during which participants complete questionnaires to assess cognitive performance and mood. Throughout the trial, participants undergo various assessments including memory, executive function, reaction time, mood, omega-3 status, and serum brain-derived neurotrophic factor BDNF levels. They will complete questionnaires, records, and diaries related to their cognitive and mood status. Safety and adherence are monitored, and the main outcome is the change in memory performance from baseline to day 112.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of AMPK Chargeae, a dietary supplement, alone and combined with semaglutide injections, in adults with prediabetes or Type 2 Diabetes. This randomized, single-blind, controlled trial aims to compare changes in fasting blood glucose, fasting insulin, and hemoglobin A1c HbA1c after 84 days of treatment with these two approaches. Participants will take AMPK Chargeae twice daily on an empty stomach, holding it in the mouth before swallowing. Some participants will also receive weekly subcutaneous injections of semaglutide, starting at 0.25 mg for four weeks, then increasing to 0.5 mg for the rest of the 84-day period. The study compares these two groups to assess differences in blood sugar control. During the study, participants will undergo regular assessments of blood glucose, insulin levels, HbA1c, and other markers related to insulin resistance, cholesterol, inflammation, body weight, and cardiovascular risk. These measures will be taken at baseline, day 42, and day 84. Participants will complete questionnaires and diaries and attend clinic visits to monitor their progress and safety throughout the trial, which starts in February 2026 and ends in September 2026.
1-10 of 448
1